1086063-18-4

Basic information

• Product Name: Quinoline, 6-bromo-4-(4-pyridazinyl)-
• Synonyms: 6-Bromo-4-(4-pyridazinyl)quinoline;6-broMo-4-(pyridazin-4-yl)quinoline;Quinoline, 6-bromo-4-(4-pyridazinyl)-;(24E)-3-OXOLANOSTA-7,9(11),24-TRIEN-26-OIC ACID
• CAS NO: 1086063-18-4
• Molecular Formula: C13H8BrN3
• Molecular Weight: 286.13
• EINECS: 200-258-5
• Mol File: 1086063-18-4.mol

Chemical Properties

• Boiling Point: 487.9±45.0 °C(Predicted)
• Appearance: /
• Density: 1.549±0.06 g/cm3(Predicted)
• PKA: 2.15±0.49(Predicted)
• CAS DataBase Reference: Quinoline, 6-bromo-4-(4-pyridazinyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Quinoline, 6-bromo-4-(4-pyridazinyl)-(1086063-18-4)
• EPA Substance Registry System: Quinoline, 6-bromo-4-(4-pyridazinyl)-(1086063-18-4)

Safety Data

• Hazardous Substances Data: 1086063-18-4(Hazardous Substances Data)

Usage

Uses

Since the provided materials do not explicitly mention the uses of Quinoline, 6-bromo-4-(4-pyridazinyl)-, it is not possible to list its applications based on the given information. However, as with other quinolines, it may have potential applications in various fields such as pharmaceuticals, materials science, or as an intermediate in the synthesis of other compounds. Further research and information would be required to confirm its specific uses and applications.

Upstream product

• 65340-70-7 6-bromo-4-chloroquinoline 
• 927801-23-8 6-bromo-4-iodoquinoline 
• 194865-89-9 4-(tributylstannanyl)pyridazine 
• 1086062-75-0 6-bromo-4-chloroquinoline hydrochloride 
• 145369-94-4 6-bromo-3-quinolinecarboxylic acid-4-ol 
• 187278-01-9 5-(((4-bromophenyl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 

Downstream Products

• 1086062-66-9 GS⁽²⁶⁴⁾K₂₁₅₈ 
• 1360537-71-8 4-fluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)-2-nitrobenzenesulfonamide 
• 1360537-72-9 2-fluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)-4-nitrobenzenesulfonamide 
• 1360537-73-0 2,4-difluoro-N-(2-hydroxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1360537-75-2 2-[⁽¹⁸⁾F]fluoro-4-fluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1360537-76-3 2-fluoro-4-[⁽¹⁸⁾F]fluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide 

Relevant articles and documents

METHOD OF ADMINISTRATION AND TREATMENT

The present invention provides a method of treating a human with cancer comprising detecting at least one mutation in a PIK3CA gene or at least one mutant protein encoded by said PIK3CA gene from at least one first sample from said human and administering to said human an effective amount of 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide or a pharmaceutically acceptable salt thereof in a pharmaceutical composition if said at least one sample has at least one mutant PI3K protein or a mutation in the PIK3CA gene.

[11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers

GSK2126458 is a highly potent inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) with low picomolar to subnanomolar activity. [11C]GSK2126458 and [18F]GSK212 6458, new potential PET agents for imaging of PI3K and mTOR in cancer, were first designed and synthesized in 40-50% and 20-30% decay corrected radiochemical yield, and 370-740 and 37-222 GBq/lmol specific activity at end of bombardment (EOB), respectively.